Organogenesis (NASDAQ:ORGO) Shares Down 6.2% - Should You Sell?

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report)'s share price fell 6.2% during trading on Tuesday . The company traded as low as $4.99 and last traded at $5.08. 988,595 shares traded hands during mid-day trading, a decline of 6% from the average session volume of 1,055,866 shares. The stock had previously closed at $5.41.

Analysts Set New Price Targets

Separately, Morgan Stanley raised their target price on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Wednesday.

Organogenesis Trading Down 8.5 %

The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The stock has a fifty day simple moving average of $3.65 and a 200 day simple moving average of $3.35. The firm has a market capitalization of $654.43 million, a P/E ratio of -86.00 and a beta of 1.66.

Insider Buying and Selling at Organogenesis

In other news, CEO Gary S. Gillheeney sold 157,448 shares of Organogenesis stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $3.64, for a total value of $573,110.72. Following the sale, the chief executive officer now directly owns 3,143,753 shares of the company's stock, valued at approximately $11,443,260.92. The trade was a 4.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares in the company, valued at $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 284,700 shares of company stock valued at $1,051,472 over the last ninety days. 36.90% of the stock is currently owned by company insiders.

Remove Ads

Institutional Investors Weigh In On Organogenesis

Several large investors have recently made changes to their positions in ORGO. Assenagon Asset Management S.A. grew its position in Organogenesis by 54.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock worth $9,443,000 after acquiring an additional 1,035,120 shares in the last quarter. Soleus Capital Management L.P. grew its position in Organogenesis by 5.4% in the fourth quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock worth $39,952,000 after acquiring an additional 645,000 shares in the last quarter. Norges Bank purchased a new position in Organogenesis in the fourth quarter worth about $1,543,000. Dimensional Fund Advisors LP grew its position in Organogenesis by 18.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock worth $8,925,000 after acquiring an additional 442,772 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Organogenesis by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company's stock worth $3,435,000 after acquiring an additional 255,600 shares in the last quarter. 49.57% of the stock is owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.